These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 16759769

  • 1. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years.
    Black S, Friedland LR, Schuind A, Howe B, GlaxoSmithKline DTaP-IPV Vaccine Study Group.
    Vaccine; 2006 Aug 28; 24(35-36):6163-71. PubMed ID: 16759769
    [Abstract] [Full Text] [Related]

  • 2. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S, Friedland LR, Ensor K, Weston WM, Howe B, Klein NP.
    Pediatr Infect Dis J; 2008 Apr 28; 27(4):341-6. PubMed ID: 18316985
    [Abstract] [Full Text] [Related]

  • 3. A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years.
    Marshall H, Nolan T, Roberton D, Richmond P, Lambert S, Jacquet JM, Schuerman L.
    Vaccine; 2006 Aug 28; 24(35-36):6120-8. PubMed ID: 16822597
    [Abstract] [Full Text] [Related]

  • 4. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children.
    Klein NP, Weston WM, Kuriyakose S, Kolhe D, Howe B, Friedland LR, Van Der Meeren O.
    Vaccine; 2012 Jan 11; 30(3):668-74. PubMed ID: 22064267
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
    Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E.
    Southeast Asian J Trop Med Public Health; 2009 Mar 11; 40(2):282-94. PubMed ID: 19323013
    [Abstract] [Full Text] [Related]

  • 6. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
    Guerra FA, Blatter MM, Greenberg DP, Pichichero M, Noriega FR, Pentacel Study Group.
    Pediatrics; 2009 Jan 11; 123(1):301-12. PubMed ID: 19117896
    [Abstract] [Full Text] [Related]

  • 7. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY, Wang YH, Huang YC, Chiu CH, Lin PY, Chen CJ, Chavand P, Ortiz E.
    Int J Infect Dis; 2007 Nov 11; 11(6):488-95. PubMed ID: 17349809
    [Abstract] [Full Text] [Related]

  • 8. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM, Predy G, Guasparini R, Law B, Diaz-Mitoma F, Whitstitt P, Tapiero B, Dionne M, Tomovici A, Mills E, Halperin SA.
    Vaccine; 2007 Jan 22; 25(6):1121-5. PubMed ID: 17045366
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY, Hwang HS, Kim JH, Kim HH, Lee HS, Chung EH, Park SE, Ma SH, Chang JK, Guitton F, Ortiz E, Kang JH.
    Vaccine; 2011 Feb 11; 29(8):1551-7. PubMed ID: 21215828
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
    Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gómez-Campderá JA, Navarro ML, Merino JM, Martín-Ancel A, Roca J, García-del-Río M, Jurado A, Díez-Delgado FJ, Omeñaca F, García-Sicilia J, Boceta R, García-Corbeira P, Jacquet JM, Collard A, Schuerman L, Spanish DTaP-HBV-IPV-097 Study Group.
    Pediatr Infect Dis J; 2006 Aug 11; 25(8):713-20. PubMed ID: 16874171
    [Abstract] [Full Text] [Related]

  • 11. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).
    Johns TL, Hutter GE.
    Ann Pharmacother; 2010 Mar 11; 44(3):515-23. PubMed ID: 20197476
    [Abstract] [Full Text] [Related]

  • 12. Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: a randomized, controlled trial in children primed according to a 2 + 1 schedule in infancy.
    Ferrera G, Cuccia M, Mereu G, Icardi G, Bona G, Esposito S, Marchetti F, Messier M, Kuriyakose S, Hardt K.
    Hum Vaccin Immunother; 2012 Mar 11; 8(3):355-62. PubMed ID: 22327497
    [Abstract] [Full Text] [Related]

  • 13. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R, Kuriyakose S, Mesaros N, Han HH, Tomlinson R, Faust SN, Snape MD, Pollard AJ, Finn A.
    Vaccine; 2018 Apr 19; 36(17):2300-2306. PubMed ID: 29576304
    [Abstract] [Full Text] [Related]

  • 14. Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers.
    Halperin SA, Tapiero B, Law B, Diaz-Mitoma F, Duval B, Langley JM, Elrick DB, Jacquet JM.
    Vaccine; 2006 May 01; 24(18):4017-23. PubMed ID: 16516357
    [Abstract] [Full Text] [Related]

  • 15. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M, Habermehl P, Faber J, Bock HL, Sänger R, Bogaerts H, Clemens R, Schuind A, du Prel JB, Schmitt HJ.
    Vaccine; 2006 Jul 07; 24(27-28):5627-36. PubMed ID: 16740348
    [Abstract] [Full Text] [Related]

  • 16. Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China.
    Li RC, Li FX, Li YP, Hou QM, Li CG, Li YN, Chen FS, Hu XZ, Su WB, Zhang SM, Fang HH, Ye Q, Zeng TD, Liu TX, Li XB, Huang YN, Deng ML, Zhang YP, Ortiz E.
    Vaccine; 2011 Nov 21; 29(50):9337-44. PubMed ID: 22001281
    [Abstract] [Full Text] [Related]

  • 17. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely.
    Omeñaca F, Garcia-Sicilia J, Boceta R, Sistiaga-Hernando A, García-Corbeira P.
    Pediatr Infect Dis J; 2007 Sep 21; 26(9):824-9. PubMed ID: 17721379
    [Abstract] [Full Text] [Related]

  • 18. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
    Lin TY, Wang YH, Chang LY, Huang YC, Kao HT, Lin PY, Lu HK, Chavand P, Ortiz E.
    Int J Infect Dis; 2007 Mar 21; 11(2):129-36. PubMed ID: 16762579
    [Abstract] [Full Text] [Related]

  • 19. A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration.
    MMR-158 Study Groupa See Contributors section..
    Hum Vaccin Immunother; 2019 Mar 21; 15(4):786-799. PubMed ID: 30785357
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
    Pichichero ME, Bernstein H, Blatter MM, Schuerman L, Cheuvart B, Holmes SJ, 085 Study Investigators.
    J Pediatr; 2007 Jul 21; 151(1):43-9, 49.e1-2. PubMed ID: 17586189
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.